No worries - but they are all coming from City of Hope and specifically both CAR-T's come back to Christine BRown. CHM benefits from the work done on the earlier CAR-T even though we didn't acquire it.
The CAR-T used on Dr Richard Grady targeting IL13Rα2 was the first time CAR-T cells were administered intraventricularly into a human brain i.e. into the cavity within the brain.
The benefit of intraventricular administration is that it can mitigate tumor cells escaping the immediate surroundings of the tumor to other parts of the brain, as well as mitigating the chance of it circulating throughout the body.
GBM cells will always grow back even after you cut it away... that is because the GBM cells embed themselves throughout the brain/body. So cutting it away will only provide temporary relief... which is why hitting it broadly and not just intratumorally will increase the chance of a positive outcome for the patient.
CHM Price at posting:
32.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)